» Articles » PMID: 32240330

Toxicology Data of Graphene-family Nanomaterials: an Update

Overview
Journal Arch Toxicol
Specialty Toxicology
Date 2020 Apr 3
PMID 32240330
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Due to its unique physical structure and chemical properties, graphene family nanomaterials (GFNs) and derived commodities have been widely used in commercial products, particularly biomedical applications, which has significantly increased the risk of human exposure. There exists significant evidence that GFNs are accumulated in a number of tissues and organs through different exposure pathways, and further cause toxicity manifested as lesions or functional impairment. Moreover, GFNs can be internalized by varing cell types and induce cytoskeletal disorders, organelle dysfunction, and interact directly with biological macromolecules such as DNA, mRNA and proteins, ultimately resulting in greater rates of cell apoptosis, necrosis and autophagic cell death. The toxicological effect of GFN is closely related to its lateral size, surface structure, functionalization, and propensity to adsorb proteins. Using major data published over the past four years, this review presents and summarizes state of current understanding of GFN toxicology and identifies current deficiencies and challenges. This review aims to help improve evaluation of the biocompatibility of GFNs and provides theoretical guidance for their safe application.

Citing Articles

Angiotensin II-Induced Hypertrophy in H9c2 Cells Reveals Severe Cytotoxicity of Graphene Oxide.

Luna-Figueroa E, Bernal-Ramirez J, Vazquez-Garza E, Huerta-Arcos L, Garcia-Rivas G, Contreras-Torres F ACS Omega. 2025; 10(7):7327-7337.

PMID: 40028060 PMC: 11866173. DOI: 10.1021/acsomega.4c11130.


A Graphene-Based Bioactive Product with a Non-Immunological Impact on Mononuclear Cell Populations from Healthy Volunteers.

Lavin-Lopez M, Torres-Torresano M, Garcia-Cuesta E, Soler-Palacios B, Griera M, Martinez-Rovira M Nanomaterials (Basel). 2024; 14(23).

PMID: 39683333 PMC: 11643509. DOI: 10.3390/nano14231945.


Microwave radiofrequencies, 5G, 6G, graphene nanomaterials: Technologies used in neurological warfare.

Deruelle F Surg Neurol Int. 2024; 15:439.

PMID: 39640342 PMC: 11618680. DOI: 10.25259/SNI_731_2024.


Graphene Quantum Dots from Natural Carbon Sources for Drug and Gene Delivery in Cancer Treatment.

Osorio H, Castillo-Solis F, Barragan S, Rodriguez-Polit C, Gonzalez-Pastor R Int J Mol Sci. 2024; 25(19).

PMID: 39408866 PMC: 11476599. DOI: 10.3390/ijms251910539.


On the Use of Nanoparticles in Dental Implants.

Bokobza L Materials (Basel). 2024; 17(13).

PMID: 38998274 PMC: 11242106. DOI: 10.3390/ma17133191.


References
1.
Adjei I, Sharma B, Labhasetwar V . Nanoparticles: cellular uptake and cytotoxicity. Adv Exp Med Biol. 2014; 811:73-91. DOI: 10.1007/978-94-017-8739-0_5. View

2.
Aggarwal P, Hall J, McLeland C, Dobrovolskaia M, McNeil S . Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev. 2009; 61(6):428-37. PMC: 3683962. DOI: 10.1016/j.addr.2009.03.009. View

3.
Akhavan O, Ghaderi E . Toxicity of graphene and graphene oxide nanowalls against bacteria. ACS Nano. 2010; 4(10):5731-6. DOI: 10.1021/nn101390x. View

4.
Amrollahi-Sharifabadi M, Koohi M, Zayerzadeh E, Hablolvarid M, Hassan J, Seifalian A . In vivo toxicological evaluation of graphene oxide nanoplatelets for clinical application. Int J Nanomedicine. 2018; 13:4757-4769. PMC: 6110298. DOI: 10.2147/IJN.S168731. View

5.
An W, Zhang Y, Zhang X, Li K, Kang Y, Akhtar S . Ocular toxicity of reduced graphene oxide or graphene oxide exposure in mouse eyes. Exp Eye Res. 2018; 174:59-69. DOI: 10.1016/j.exer.2018.05.024. View